Introduction
Pharmacogenetics influence the risk of relapse in childhood acute lymphoblastic leukemia (ALL) 1 .
Methotrexate (MTX) is one of the most widely used drugs in these patients [2] [3] [4] [5] and many genetic polymorphisms may influence MTX pharmacokinetics and dynamics 6 . MTX is a folic acid antagonist with increased affinity for its target enzymes when polyglutamated intracellularly.
Furthermore, the polyglutamated MTX (MTX-glu(n)) is intracellular retained far longer than the administered monoglutamated MTX. MTX and MTX-glu(n) exert their effect by inhibiting enzymes essential for thymidylate synthesis and de novo purine synthesis, which will affect DNA synthesis and cellular proliferation 7;8 . The first step, cellular uptake, involves the reduced folate carrier (RFC) 9;10 . A polymorphism, 80G>A (rs1051266, His27Arg), in the RFC gene (SLC19A1)
has been identified with an allele frequency of 0.48 11;12 . Functional studies of the polymorphism have produced somewhat ambiguous results. Whetstine et al. 13 found no significant differences in MTX uptake between RFC-allele variants in transfected cells, whereas Baslund et al. demonstrated
increased MTX uptake in cells from healthy persons with the AA variant 14 . The RFC gene is located at chromosome 21 and there appears to be a direct relationship between copy number of chromosome 21 and the risk of toxicity after MTX therapy; as patients with Down´s syndrome show more treatment-related toxicity. Furthermore, hyperdiploid B-precursor ALL patients which in >90% of the cases include three or four copies of chromosome 21 have a low relapse rate and they generate significantly higher intracellular levels of MTX-glu(n) in their leukemic cells compared to non-hyperdiploid patients [15] [16] [17] . These findings are likely to reflect enhanced intracellular transport of MTX, since it has been shown that the RFC gene is expressed at significantly higher levels in hyperdiploid lymphoblasts than in non-hyperdiploid lymphoblasts 18;19 . Laverdiere et al 11 in a study of 204 patients found a reduced relapse rate for patients with the Gallele. However, different MTX-treatment strategy was used in the latter study, and neither of the two studies explored the impact of chromosome 21 copy number 11;22 .
In this nation-wide study comprising 500 children with ALL, we have investigated the influence of RFC (SLC19A1) polymorphism on the risk of relapse and of post-HDMTX toxicity as well as the interactions with chromosome 21 copy number.
Patients, Materials, and Methods
Patients: 563 children aged 1-15 years were diagnosed with non-mature B cell or T cell leukemia in Denmark from January 1992 to January 2007 (246 girls, 317 boys, aged 1.1-14.9 -median 4.5).
At a median follow-up time of 7.9 years (50% range: 4.1-12.1 years), 452 (80%) are still in 1 st remission, whereas 74 (13%) patients have relapsed within 0.2-8.3 years from the diagnosis (median: 2.6 years). Seventeen of the 74 relapses involved the CNS, 12 of which were isolated. Five patients died in first remission (1%) and five developed a second malignancy (1%) ( Table 1) .
Twenty-two patients died before the first HDMTX was given (4%), and five patients did not achieve remission during induction treatment and thus changed protocol before the first HDMTX (1%).
Sixty-three patients were excluded from the study due to a lack of DNA material or poor quality of DNA in the specimens (n=47), because of change of protocol (n=5) or death (n=11) before the first HDMTX course. All the remaining 500 patients included in this study, i.e. 89% of those potentially eligible in Denmark during the study period ( Therapy: The children were divided into treatment groups based on risk assessments according to the NOPHO protocol 23 . The children were considered high risk if any of the following parameters were present: white blood count (WBC) >50 x 10 9 /L, T-lineage ALL, the presence of CNS or testicular leukemia, translocations t(9;22)(q34;q11) or t(4;11)(q21;q23), lymphomatous leukemia or mediastinal lymphoma, and/or a poor treatment response (>25% blasts in BM day 15 or >5% blasts in BM day 29). Methods: Genomic DNA was extracted and purified by NaCl-and ethanol-precipitation from 1-5 ml EDTA-stabilized blood. Allelic discrimination was carried out to detect the RFC80 G>A polymorphism using fluorogenic 3'-minor groove-binding probes in an end-point PCR assay on an ABI 7500 Fast platform (Applied Biosystems, Denmark). Primers and probes were as described in an earlier study 14 . The method was validated using the BigDye terminator v1.1 cycle sequencing kit and Sanger sequencing on ABI 3730. All reagents were purchased from Applied Biosystems, Denmark. To measure MTX a photometric assay was used. ) with stratification by risk group were used to identify potential risk factors for an event. Model assumptions, including the proportionality assumption, were assessed using conventional methods A general linear model was used for pharmacokinetic analyses after the first HDMTX. Repeated measurements (mixed model analysis), with the order of HDMTX courses as a random effect, were used to explore toxicity and pharmacokinetic after all HDMTX courses. Each low risk patient had from one to nine HDMTX courses and each high risk patients one to three courses. In the statistical tests, all data was logarithmically transformed and adjustment for low/high risk group was applied.
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Chi 2 test were used for tests of independence to determine RFC polymorphism and risk of developing leukemia.
Results

Risk of developing leukemia:
We found no significant differences in the RFC allele frequencies between the 516 patients and the 200 blood donors (p=0.44) ( Table 2 ) and patients RFC frequencies were in agreement with Hardy-Weinberg equilibrium. (Table 3) .
Event risk by RFC
Toxicity after high-dose methotrexate:
To investigate the impact of RFC80 polymorphism on toxicity after HDMTX, the highest level of ALAT and the nadir of neutrophils, platelets and hemoglobin within a month after HDMTX or Page 12/24 before the next HDMTX (if earlier) were available for 182 patients. Low risk patients in the AA variant group had significantly lower platelets (p=0.004/0.002) and hemoglobin nadirs (p=0.004/0.001) compared to the GA and GG variant groups and the levels of ALAT were significantly higher in the GG variant group compared to the GA and AA variant groups (p=0.030/0.049) ( Table 4 ). The same trends were seen in high risk patients although it did not reach statistical significance. If only relapse was considered as an event, then p=0.13. 2 Low risk patients were excluded from the model, because no T-ALL were assigned to low risk therapy 3 P-value of covariate if included in the final model
Pharmacokinetics:
To explore the pharmacokinetic impact of the RFC80 polymorphism we analysed 182 patients, all treated at Rigshospitalet, Copenhagen, with plasma MTX levels measured at 20-24 hours after initiation of the HDMTX infusion (n=608 HDMTX courses). One houndredand-twenty-three patients had MTX measurements available from their first HDMTX. These patients did not differ significantly from the remaining total study cohort with respect to gender, treatment protocol, immunophenotype or relapse rate. Patients with the GG-variant had lower end-of-infusion plasma MTX-levels (Table 5 ) than the others variant groups both at the first HDMTX course (p=0.0365, 123 patients stratified for low/high risk ALL), and after all HDMTX courses (p=0.0122, 608 HDMTX courses, 182 patients). 
Discussion
This study not only indicates a significant impact of RFC 80G>A polymorphism on MTX treatment efficacy in childhood ALL, but as important emphasizes that these results can only be fully appreciated within the karyotypic background of the leukemic cells.
Other studies have explored variations in the RFC expression in leukemic cells 19 and demonstrated that low expression of RFC is related to a poor outcome in childhood leukemia 27 . Furthermore, Belkov et al showed that higher mRNA levels of RFC were related to the chromosome 21 copy number 18 and Jansen et al. suggested that higher mRNA levels was related to the RFC80 A variant and to the chromosome 21 copy number 28 . This is in conformity with both the results in Baslund´s study, where the RFC80 AA variant takes up MTX more efficiently, and the clinical results of the present study, where higher numbers of chromosome 21 seem to neutralize the effect of RFC variants.
In contrast to the present study, Laverdiere et al. 11 found an association between variant A alleles and a worse outcome in childhood leukemia. However, in their study only one 4 g/m 2 HDMTX course and 30mg/m 2 per week after induction was given instead of the four to nine courses of 5 or 8 g/m 2 HDMTX courses and 20mg/m 2 per week after induction used in the NOPHO protocols. Furthermore, the present study includes twice as many patients and the median follow up time is much longer (7.9 versus 4 years), which is important since relapses tend to come late in many low risk ALL patients such as the high-hyperdiploid cases and those with t(12;21) 25 .
However, we confirmed the association between the RFC GG variant and lower MTX plasma concentrations reported by Laverdiere et al 11 . Furthermore, we found that low risk patients had more post-HDMTX liver toxicity (higher ALAT levels) in the GG variant group compared to patients with GA/AA variants. The biological background for this association is unclear. However, A new study by De Jonge et al 29 has shown a correlation between variants in the RFC80 polymorphism and the etiology of leukemia and although it was not the purpose of this study, we looked at the correlation, but found no connection between the RFC allele frequencies and etiology of childhood leukemia.
Conclusion
This study emphasizes the need to add pharmacogenetic profiling to the already extensive biological exploration of childhood ALL, since both these and previously published data 30 support that individual variations in genes that influence the disposition of anticancer agents may be as important for the risk of relapse as the genetic aberrations of the leukemic clone. Although this study showed significant association between RFC genotypes and outcome, these results need to be validated in an independent patient cohort. Further studies looking at the interaction between pharmacogenetic polymorphisms and risk of treatment failure are needed to determine whether adjusting the drug dosing according to genotype will increase the efficacy of the antileukemic treatment. Such studies are ongoing in the study group and some are now integrated into the NOPHO ALL2008 protocol.
